Alebachew Ferede Zegeye, Tadesse Tarik Tamir, Enyew Getaneh Mekonen, Mohammed Seid Ali, Almaz Tefera Gonete, Masresha Asmare Techane, Mulugeta Wassie, Alemneh Tadesse Kassie, Medina Abdela Ahmed, Sintayehu Simie Tsega, Yilkal Abebaw Wassie, Berhan Tekeba, Belayneh Shetie Workneh
Number of tetanus toxoid injections before birth and associated factors among pregnant women in low and middle income countries: Negative binomial poisson regression
Human vaccines & immunotherapeutics
data monitoring committees dmcs integral part clinical drug development use evolved along changing study designs regulatory expectations associated statistical ethical implications although guidance different regulatory agencies opportunities bring consistency address practical issues establishing operating dmc challenging issues include defining scope dmc decisions regulatory requirements expectations perceived independence dmcs specific focus primarily safety etc wider use adaptive clinical trial designs recent years introduce additional challenges terms trial governance complexity dmc activities panel comprised clinical statistical experts across academia industry regulatory agencies shared experience thoughts importance aspects offered perspectives future dmcs paper documents thinking panel session cenisbs conference held vienna austria 2017